DDInter1024 DDInter734
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora. The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.
Lapatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Lapatinib {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Lapatinib {u} (Compound) upregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) interacts with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Amprenavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Amprenavir {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Amlodipine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Fidaxomicin
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Amlodipine {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fidaxomicin
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Sunitinib {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Fidaxomicin
Lapatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Lapatinib (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Fidaxomicin (Compound)
Lapatinib (Compound) upregulates PSMB8 (Gene) and PSMB8 (Gene) interacts with ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Lapatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Lapatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Lapatinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Fidaxomicin (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fidaxomicin (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Fidaxomicin (Compound)